{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:30:13Z","timestamp":1780450213210,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e. pregnancy) often necessitate individualized antiretroviral therapy (ART) regimens. This study aimed to characterize United States HIV provider strategies for ART selection when faced with concomitant health conditions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A survey of US HIV providers was conducted using hypothetical patient cases. Standardized clinical case-vignettes were developed and providers were asked to select their preferred regimen. Eleven cases focused on cardiometabolic syndrome, renal dysfunction, weight gain, and pregnancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>119 providers responded across all cases (with a median 57 responses [interquartile range 55.5\u201372] per case), and were primarily Infectious Diseases physicians in academic settings from across the continental United States. Bictegravir\/tenofovir alafenamide\/emtricitabine was most commonly prescribed for three case-scenarios of cardiometabolic disease (62.3%). Diverse regimens were recommended for a case involving weight gain, with 98.5% switching from dolutegravir plus tenofovir alafenamide\/emtricitabine, most commonly to doravirine\/tenofovir disoproxil fumarate\/lamivudine. Dolutegravir-based regimens were selected in case-scenarios of pregnancy (77.3%), with some use of bictegravir\/tenofovir alafenamide\/emtricitabine (13.6%). For two case-scenarios renal disease with worsening creatinine clearance to &lt;\u200930 mL\/minute, many providers used lamivudine or emtricitabine in fixed-dose combination (43.3%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study reveals varied ART approaches for people living with HIV and non-infectious conditions, often diverging from standard regimens. While guidelines provide a framework, providers adapt treatment based on patient needs. Further research is crucial to optimize ART management in these complex situations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12981-025-00724-w","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T08:26:48Z","timestamp":1740817608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions"],"prefix":"10.1186","volume":"22","author":[{"given":"Sonya","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina B. Martinez","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Lippincott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maunank","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"724_CR1","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva, Switzerland: World Health Organization. 2021.https:\/\/www.who.int\/publications\/i\/item\/9789240031593 October 30, 2024."},{"key":"724_CR2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2024.https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv"},{"key":"724_CR3","doi-asserted-by":"crossref","unstructured":"Gandhi RT, Landovitz RJ, Sax PE et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international antiviral Society-USA panel. JAMA 2025 Feb 18;333(7):609\u201328. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39616604.","DOI":"10.1001\/jama.2024.24543"},{"issue":"3","key":"724_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/QAD.0000000000003128","volume":"36","author":"KN Althoff","year":"2022","unstructured":"Althoff KN, Stewart CN, Humes E, et al. The shifting age distribution of people with HIV using antiretroviral therapy in the united States. AIDS. 2022;36(3):459\u201371.","journal-title":"AIDS"},{"issue":"3","key":"724_CR5","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2666-7568(22)00041-1","volume":"3","author":"The Lancet Healthy L","year":"2022","unstructured":"The Lancet Healthy L. Ageing with HIV. Lancet Healthy Longev. 2022;3(3):e119.","journal-title":"Lancet Healthy Longev"},{"issue":"4","key":"724_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/QAI.0000000000000662","volume":"69","author":"J Young","year":"2015","unstructured":"Young J, Xiao Y, Moodie EE, et al. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2015;69(4):413\u201321.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"724_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of Tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496\u2013505.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"724_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11904-024-00688-y","volume":"21","author":"AN Goulding","year":"2024","unstructured":"Goulding AN, Meeks K, Shay L, Casey S, Applegarth C, McKinney J. Antiretroviral therapy in pregnancy: A 2023 review of the literature. Curr HIV\/AIDS Rep. 2024;21(1):1\u201310.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"11","key":"724_CR9","doi-asserted-by":"publisher","first-page":"ofad541","DOI":"10.1093\/ofid\/ofad541","volume":"10","author":"S Krishnan","year":"2023","unstructured":"Krishnan S, Lippincott CK, Bjerrum S, Martinez Rivera MB, Shah M. A National HIV provider survey of antiretroviral therapy preferences for management of Treatment-Naive and experienced individuals with drug resistance. Open Forum Infect Dis. 2023;10(11):ofad541.","journal-title":"Open Forum Infect Dis"},{"key":"724_CR10","doi-asserted-by":"crossref","unstructured":"Horberg M, Thompson M, Agwu A et al. Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis 2024; https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39393187","DOI":"10.1093\/cid\/ciae479"},{"issue":"11","key":"724_CR11","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and Meta-Analysis. Circulation. 2018;138(11):1100\u201312.","journal-title":"Circulation"},{"issue":"1","key":"724_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1186\/s12879-021-06479-9","volume":"21","author":"PE Plum","year":"2021","unstructured":"Plum PE, Maes N, Sauvage AS, et al. Impact of switch from Tenofovir disoproxil fumarate-based regimens to Tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect Dis. 2021;21(1):910.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"724_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ijantimicag.2018.07.010","volume":"52","author":"K Dorjee","year":"2018","unstructured":"Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents. 2018;52(5):541\u201353.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"724_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/cid\/ciad545","volume":"78","author":"SH Bares","year":"2024","unstructured":"Bares SH, Wu X, Tassiopoulos K, et al. Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease. Clin Infect Dis. 2024;78(2):395\u2013401.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"724_CR15","doi-asserted-by":"publisher","first-page":"e25702","DOI":"10.1002\/jia2.25702","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon PW, Brunet L, Hsu RK, et al. Weight gain before and after switch from TDF to TAF in a U.S. Cohort study. J Int AIDS Soc. 2021;24(4):e25702.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"724_CR16","doi-asserted-by":"publisher","first-page":"ofae007","DOI":"10.1093\/ofid\/ofae007","volume":"11","author":"S Sokhela","year":"2024","unstructured":"Sokhela S, Venter WDF, Bosch B, et al. Final 192-Week efficacy and safety results of the ADVANCE trial, comparing 3 First-line antiretroviral regimens. Open Forum Infect Dis. 2024;11(3):ofae007.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"724_CR17","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"724_CR18","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/cid\/ciac949","volume":"76","author":"B Bosch","year":"2023","unstructured":"Bosch B, Akpomiemie G, Chandiwana N, et al. Weight and metabolic changes after switching from Tenofovir Alafenamide\/Emtricitabine (FTC)\u2009+\u2009Dolutegravir (DTG), Tenofovir disoproxil fumarate (TDF)\/FTC\u2009+\u2009DTG, and TDF\/FTC\/Efavirenz to TDF\/Lamivudine\/DTG. Clin Infect Dis. 2023;76(8):1492\u20135.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"724_CR19","first-page":"990","volume":"79","author":"J Damas","year":"2024","unstructured":"Damas J, Munting A, Fellay J, et al. Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing Tenofovir Alafenamide in people with HIV. Clin Infect Dis. 2024;79(4):990\u20138.","journal-title":"Clin Infect Dis"},{"key":"724_CR20","doi-asserted-by":"crossref","unstructured":"Anderson D, Ramgopal M, Hagins DP et al. DEFINE: A prospective, randomized, phase 4 trial to assess a protease Inhibitor-based regimen switch strategy to manage integrase Inhibitor-related weight gain. Clin Infect Dis 2024; https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39230668","DOI":"10.1093\/cid\/ciae449"},{"key":"724_CR21","doi-asserted-by":"crossref","unstructured":"Olivero R, Williams PL, Sawyer G et al. Birth outcomes following bictegravir exposure during pregnancy. AIDS 2024; https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39411892","DOI":"10.1097\/QAD.0000000000004041"},{"key":"724_CR22","unstructured":"Gilead Sciences. EMTRIVA (emtricitabine) [package insert]. 2003.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021500s019lbl.pdf December 3, 2024."},{"key":"724_CR23","unstructured":"GlaxoSmithKline. EPIVIR (lamivudine) [package insert]. Research Triangle Park, NC, USA. 1995.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020564s37_020596s036lbl.pdf December 3, 2024."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00724-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00724-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00724-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T08:26:53Z","timestamp":1740817613000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00724-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00724-w","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Johns Hopkins University Institutional Review Board. All participants affirmed their consent to participate through a survey question.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}